VRTX
$76.75
Vertex Pharmaceutic
$1.25
1.66%

Earnings History

Earnings
Revenue
Reaction
Drift
In-line Guidance
FY 2013
1/29/2013
4:01:01 PM
-3.8%
-1.4%
Guidance:
Consensus:
Vertex Pharmaceuticals Sees Revenue In-line

Vertex Pharmaceuticals Inc. said it expects 2013 revenue of $1.10 billion to $1.25 billion. The current consensus estimate is revenue of $1.21 billion for the year ending December 31, 2013.
Reaffirms
FY 2013
4/30/2013
4:03:01 PM
$1.10 bil to $1.25 bil
$1.16 bil
0.0%
-2.5%
Guidance:
Consensus:
Vertex Pharmaceuticals Reaffirms

Vertex Pharmaceuticals Inc. said it continues to expect 2013 revenue of $1.10 billion to $1.25 billion. The current consensus estimate is revenue of $1.16 billion for the year ending December 31, 2013.
Narows Guidance
FY 2013
7/29/2013
4:00:13 PM
$1.10 bil to $1.20 bil
$1.20 bil
2.8%
-5.1%
Guidance:
Consensus:
Vertex Pharmaceuticals Narrows Guidance

Vertex Pharmaceuticals Inc. said it expects 2013 revenue of $1.10 billion to $1.20 billion. The company's previous guidance was revenue of $1.10 billion to $1.25 billion and the current consensus estimate is revenue of $1.20 billion for the year ending December 31, 2013.
Revenue Below Estimates
FY 2014
1/13/2014
4:13:27 AM
-1.5%
9.8%
Guidance:
Consensus:
Vertex Pharmaceuticals Sees 2014 Revenue Below Estimates

Vertex Pharmaceuticals Inc. said it expects 2014 revenue of $570.0 million to $600.0 million. The current consensus estimate is revenue of $687.4 million for the year ending December 31, 2014.
Reaffirms Below Estimates
FY 2014
1/29/2014
4:01:14 PM
4.2%
-3.3%
Guidance:
Consensus:
Vertex Pharmaceuticals Reaffirms Below Estimates

Vertex Pharmaceuticals Inc. said it continues to expect 2014 revenue of $570.0 million to $600.0 million. The current consensus estimate is revenue of $631.1 million for the year ending December 31, 2014.
Revenue Below Estimates
FY 2014
5/1/2014
4:02:21 PM
$520.0 mil to $550.0 mil
$594.2 mil
-3.7%
-5.9%
Guidance:
Consensus:
Vertex Pharmaceuticals Lowers Guidance

Vertex Pharmaceuticals Inc. said it expects 2014 revenue of $520.0 million to $550.0 million. The company's previous guidance was revenue of $570.0 million to $600.0 million and the current consensus estimate is revenue of $594.2 million for the year ending December 31, 2014.
Reaffirms
FY 2014
7/29/2014
4:01:41 PM
$520.0 mil to $550.0 mil
$543.2 mil
-3.7%
-7.2%
Guidance:
Consensus:
Vertex Pharmaceuticals Reaffirms

Vertex Pharmaceuticals Inc. said it continues to expect 2014 revenue of $520.0 million to $550.0 million. The current consensus estimate is revenue of $543.2 million for the year ending December 31, 2014.
Revenue Below Estimates
FY 2016
9/28/2016
4:40:00 PM
-4.3%
-3.9%
Guidance:
Consensus:
Vertex Pharmaceuticals Lowers Revenue Guidance

Vertex Pharmaceuticals Inc. said it now expects 2016 ORKAMBI revenue of $950.0 million to $990.0 million. The company's previous guidance was for 2016 ORKAMBI revenue of $1.0 billion to $1.1 billion. The new guidance implies 2016 product revenue of 1.635 billion to $1.695 billion. The company's previous guidance was for revenue of $1.685 billion to $1.805 billion and the current consensus revenue estimate is $1.81 billion for the year ending December 31, 2016.
Reaffirms
FY 2016
10/25/2016
4:03:10 PM
0.0%
-4.8%
Guidance:
Consensus:
Vertex Pharmaceuticals Reaffirms

Vertex Pharmaceuticals Inc. said it continues to expect ORKAMBI revenue of $950.0 million to $990.0 million and KALYDECO revenue of $685.0 million to $705.0 million for combined product revenue of 1.635 billion to $1.695 billion. The current consensus estimate is revenue of $1.71 billion for the year ending December 31, 2016.
Date
Grade
Actual
Earnings
Whisper
Consensus
Estimate
Surprise
Growth
Gap
Drift
2/2/2012
4:00:10 PM
Dec '11
Q4 '11
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G F
EPS
Rev
$0.75
$563.34 Mil
-
$0.75
$523.66 Mil
-
7.6%
-
759.7%
-2.2%
-3.8%
4/26/2012
4:00:05 PM
Mar '12
Q1 '12
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G F
EPS
Rev
$0.41
$438.74 Mil
$0.55
$0.56
$467.78 Mil
-25.5%
-6.2%
-
495.6%
-1.7%
1.4%
7/30/2012
4:03:01 PM
Jun '12
Q2 '12
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G F
EPS
Rev
$0.33
$418.31 Mil
-
$0.57
$483.42 Mil
-42.1%
-13.5%
-
265.6%
-0.4%
3.5%
11/1/2012
3:58:00 PM
Sep '12
Q3 '12
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G F
EPS
Rev
$0.00
$336.01 Mil
$0.21
$0.19
$382.91 Mil
-100.0%
-12.2%
-99.4%
-49.0%
-9.8%
-1.2%
1/29/2013
4:01:01 PM
Dec '12
Q4 '12
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G D-
EPS
Rev
($0.08)
$333.99 Mil
-
($0.13)
$319.36 Mil
38.5%
4.6%
-
-40.7%
0.3%
-1.4%
4/30/2013
4:03:01 PM
Mar '13
Q1 '13
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G D-
EPS
Rev
($0.12)
$328.37 Mil
-
($0.17)
$308.61 Mil
29.4%
6.4%
-
-25.2%
0.7%
-2.5%
7/29/2013
4:00:13 PM
Jun '13
Q2 '13
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G F
EPS
Rev
($0.22)
$310.75 Mil
-
($0.21)
$307.97 Mil
-4.8%
0.9%
-
-25.7%
2.3%
-5.1%
10/29/2013
8:04:00 AM
Sep '13
Q3 '13
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G F
EPS
Rev
($0.46)
$221.70 Mil
-
($0.39)
$277.28 Mil
-17.9%
-20.0%
-
-34.0%
-2.2%
-14.1%
1/29/2014
4:01:14 PM
Dec '13
Q4 '13
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G F
EPS
Rev
($0.66)
$351.16 Mil
-
($0.57)
$215.27 Mil
-15.8%
63.1%
-
5.1%
2.5%
-3.3%
5/1/2014
4:02:21 PM
Mar '14
Q1 '14
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G F
EPS
Rev
($0.85)
$118.45 Mil
-
($0.70)
$134.04 Mil
-21.4%
-11.6%
-
-63.9%
0.2%
-5.9%
7/29/2014
4:01:41 PM
Jun '14
Q2 '14
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G F
EPS
Rev
($0.79)
$138.42 Mil
-
($0.74)
-
-6.8%
-
-
-55.5%
-2.1%
-7.2%
10/28/2014
4:02:00 PM
Sep '14
Q3 '14
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G D
EPS
Rev
($0.57)
$178.99 Mil
-
($0.57)
$146.16 Mil
-
22.5%
-
-19.3%
-0.2%
-2.0%
1/28/2015
4:01:13 PM
Dec '14
Q4 '14
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G A-
EPS
Rev
($0.73)
$144.56 Mil
-
($0.61)
$137.49 Mil
-19.7%
5.1%
-
-58.8%
-7.3%
-0.7%
4/29/2015
4:01:01 PM
Mar '15
Q1 '15
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G A
EPS
Rev
($0.86)
$138.51 Mil
-
($0.75)
$142.52 Mil
-14.7%
-2.8%
-
16.9%
0.3%
0.7%
7/29/2015
4:01:02 PM
Jun '15
Q2 '15
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G A
EPS
Rev
($0.80)
$166.08 Mil
-
($0.77)
$149.70 Mil
-3.9%
10.9%
-
20.0%
0.4%
10.6%
10/28/2015
4:01:04 PM
Sep '15
Q3 '15
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G A+
EPS
Rev
($0.40)
$309.82 Mil
-
($0.60)
$244.25 Mil
33.3%
26.8%
-
73.1%
5.4%
-3.7%
1/27/2016
4:01:03 PM
Dec '15
Q4 '15
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G A+
EPS
Rev
$0.31
$417.94 Mil
$0.15
$0.17
$401.07 Mil
106.7%
4.2%
-
189.1%
-1.6%
0.8%
4/27/2016
4:01:04 PM
Mar '16
Q1 '16
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G B+
EPS
Rev
$0.13
$398.08 Mil
$0.36
$0.30
$439.55 Mil
-63.9%
-9.4%
-
187.4%
-3.9%
3.4%
7/27/2016
4:01:03 PM
Jun '16
Q2 '16
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G B+
EPS
Rev
($0.01)
$431.61 Mil
-
($0.02)
$428.08 Mil
50.0%
0.8%
-
159.9%
-0.7%
5.2%
10/25/2016
4:03:10 PM
Sep '16
Q3 '16
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G B
EPS
Rev
($0.09)
$413.78 Mil
-
($0.06)
$419.85 Mil
-50.0%
-1.4%
-
33.6%
4.1%
-4.8%
EPS
Rev
-
-
-
$0.01
$448.64 Mil
-
-
-
7.3%
EPS
Rev
-
-
-
$0.07
$481.45 Mil
-
-
-
20.9%
2/3/2011
$38.80
($3.53)
$143.4 Mil
-
-
-
2/2/2012
$38.38
($0.49)
$1.41 Bil
-
883.9%
-1.1%
1/29/2013
$46.39
$0.68
$1.53 Bil
-
8.3%
20.9%
1/29/2014
$78.82
($1.47)
$1.21 Bil
-316.2%
-20.6%
69.9%
1/28/2015
$121.26
($2.93)
$580.4 Mil
-
-52.1%
53.8%
1/27/2016
$92.50
($2.07)
$1.03 Bil
-
77.9%
-23.7%
1/27/2017
$76.75
($0.23)
$1.71 Bil
-
65.6%
-17.0%
1/27/2018
$335.59
$0.87
$2.24 Bil
-
31.0%
337.3%
1/27/2019
-
$3.25
-
273.6%
-
-

Price Projection

Current Value
$90
17%
Projected Price
$336
337%